Holen Sie sich die Stockscreener-App
357.27
3.45%
11.90
Vorhandelsmarkt:
359.98
2.71
+0.76%
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories’ Q3 2026 Earnings: What to Expect - Yahoo Finance
Charles River Laboratories International (CRL) Has Fresh Attention, But What Is Behind It? - Simply Wall Street
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories International, Inc. Estimates – NYSE:CRL - TradingView
Charles River Laboratories (CRL) Partners with FDA and Labcorp t - GuruFocus
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Finviz
Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5 - Yahoo Finance
$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today - Benzinga
Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype - Timothy Sykes
Charles River Laboratories International Jumps 7.3% in Broad Rally - AlphaStreet
Charles River Labs Stock Jumps As Street Hikes Targets - StocksToTrade
Charles River Laboratories stock hits 52-week high at 333.31 USD - Investing.com
Charles River Laboratories stock hits 52-week high at 333.31 USD By Investing.com - Investing.com South Africa
Is Charles River Laboratories International Inc (CRL) Overvalued After 5.1% Rally? GF Value Says Overvalued - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Dilution adjustment of Charles River Laboratories International, Inc. – XETR:RV6 - TradingView
Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00 - ad-hoc-news.de
AI-Driven Drug Discovery Boosts Charles River Laboratories (CRL) Prospects - GuruFocus
Citrini Bets on Life Sciences Stocks After Claude AI Drug Study - Bloomberg.com
Charles River Laboratories International (CRL) Earnings Beat Puts Fair Value Back In Focus - Simply Wall Street
Charles River Laboratories International, Inc. (CRL) Options ChainYahoo Finance - Yahoo! Finance Canada
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
ETFs Are Net Sellers of Charles River (CRL) on Wednesday - Yahoo Finance
Apollo Orchestrate digitizes lab workflows - Select Science
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
CRLFuture Testing Mix Shift And Create The Future Program Will Support Stable Outlook - Simply Wall Street
Is Stem Cell Testing Deal Altering The Investment Case For Charles River Stock? - Simply Wall Street
JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310 - Yahoo Finance
Charles River partners with Magellan Stem Cells on cell therapy - Yahoo Finance
Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy - Yahoo Finance
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $324.87, Implies 8% Upside - TradingView
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera - GlobeNewswire Inc.
Form 144 CHARLES RIVER LABORATORIES INTERNATIONAL For: 12 October By Investing.com - Investing.com Canada
Is Charles River Laboratories International (CRL) Fairly Valued After The Apollo Orchestrate Launch? - Simply Wall Street
Q2 2026 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call - Business Wire
Charles River and Autolomous launch Apollo Orchestrate for digital laboratory execution - BioSpectrum Asia
Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com Nigeria
Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com
Form 4 Charles River Laboratories International, Inc For: 7 October By Investing.com - Investing.com India
Charles River Labs CEO Shannon Parisotto sells $302k in stock - Investing.com UK
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
PGNY or CRL: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Yahoo! Finance Canada
Charles River Gains 75.8% in a Year: What's Driving the Rally? - TradingView
Could Apollo Orchestrate Launch Shift Charles River Labs Stock Narrative - Simply Wall Street
1.02%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):